be visible on the BioBusiness market ISSN 2300-0228

Log in | Register

Final Report - analytica closes with record-breaking visitor attendance
The 26th analytica m...
MINICUBE PCR A NEW TOOL FOR GENETIC RESEARCH
The importance of research in our genes cannot ...
Bioeconomy drives Lodzkie. Americans are looking up to us
Close to a thousand participants, ...
Evotec signs agreement with Sanofi to advance early stage academic research into novel therapeutic candidate
Pharnext Announces Positive Topline Results from Pivotal Phase 3 Trial of PXT3003 for Treatment of Charcot-Marie-Tooth Type 1A Disease

All articles

Filters:

Show search box

2013-11-12

Vintafolide - a chance for Platinum-Resistant Ovarian Cancer treatment.

Vintafolide - a chance for Platinum-Resistant Ovarian Cancer treatment.

Merck, one of the leaders in production of pharmaceuticals, put its new medicine under review. It is called vintafolide, MK-8109 and it is an injectable drug conjugate consisting of folate (vitamin B9) linked to alkaloid chemotherapy agent, desacetylvinblastine monohydrazine (DAVLBH). ... Read more

Tags medicine , cancer , Merck , MSD , cancer targetting